Pharming公司预期2025年产品销售额将达1.7亿至1.8亿欧元,总收入达1.8亿至1.9亿欧元;预计研发投资9千万至1亿欧元

财报速递
20 Mar
财务展望 公司提供了以下关于未来业绩的指引: - 预计2025年产品销售额将增长至1.7亿至1.8亿欧元,推动整体商业业务的正现金流 - 预计2025年总收入将达到1.8亿至1.9亿欧元 - 预计2025年总研发投资为9千万至1亿欧元,这将部分通过补助资金和预期的研发税收抵免来抵消 - 持续严格关注现金管理,以支持足够的现金流应对关键节点;目标是2025年运营现金燃烧较当前下降50%以上

以上内容来自Benzinga Earnings专栏,原文如下:

Financial Outlook 

The Company provides the following guidance on its future results: 

• Product sales expected to grow to €170-180 million in 2025, driving positive cash-flows for the overall commercial business 

• Total revenues expected to reach €180-190 million in 2025 

• Total R&D investments expected between €90 - €100 million in 2025, which will be partially offset by grant fundings and anticipated R&D tax credits 

• Continued stringent focus on cash management supporting sufficient cash runway to reach key inflection points; targeting more than 50% lower operating cash burn in 2025

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10